Mineralys Therapeutics, Inc. - Common Stock (MLYS)
17.03
+0.28 (1.67%)
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in the treatment of cardiovascular and metabolic diseases
The company specializes in discovering and commercializing novel therapeutics that target mineralocorticoid receptors, a pathway that plays a significant role in regulating blood pressure and fluid balance. Through its cutting-edge research and development efforts, Mineralys aims to improve patient outcomes and enhance quality of life by providing effective solutions for conditions related to hypertension and related disorders.
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Mineralys Therapeutics' lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood pressure reductions and a strong safety profile.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. (“Mineralys” or “the Company”) (NASDAQ: MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MLYS.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. (“Mineralys” or “the Company”) (NASDAQ: MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MLYS.
LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. (“Mineralys” or “the Company”) (NASDAQ: MLYS) for violations of the securities laws.
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
